GALENA BIOPHARMA, INC. (NASDAQ:GALE) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
on June 8, 2017. At the Annual Meeting, our stockholders acted
upon the following proposals, which are described in detail in
the Proxy Statement:
|
Proposal 1: To re-elect William Ashton, Richard Chin, M.D.
and Rudolph Nisi, M.D. to our board of directors to serve as Class I Directors until the 2020 Annual Meeting of Stockholders; |
|
Proposal 2: To approve, by non-binding vote, the
compensation of our named executive officers as disclosed in the Proxy Statement; and |
|
Proposal 3: To ratify the appointment of Moss Adams LLP as
our independent registered public accounting firm for the fiscal year ending December 31, 2017. |
M.D. were re-elected as Class I Directors by the following votes:
|
FOR
|
WITHHELD
|
|
|
William Ashton
|
2,603,836
|
2,192,800
|
|
Richard Chin, M.D.
|
2,614,614
|
2,182,022
|
|
Rudolph Nisi, M.D.
|
2,582,659
|
2,213,977
|
with this proposal.
1,288,208 votes AGAINST, and 84,193 votes to ABSTAIN. In
addition, there were 19,754,144 broker non-votes in connection
with this proposal.
782,529 votes AGAINST, and 573,658 votes to ABSTAIN. There were
no broker non-votes in connection with this proposal.
About GALENA BIOPHARMA, INC. (NASDAQ:GALE)
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.
